Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 71 to 80 of 112

TitleReference numberPublishedLast updated
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and managementNG206
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)TA745
Nintedanib for treating progressive fibrosing interstitial lung diseasesTA747
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapyTA736
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16sNG202

Results per page

  1. 10
  2. 25
  3. 50
  4. All